Ocular Therapeutix, Inc. (OCUL)

Market Cap	1.13B
Revenue (ttm)	63.72M
Net Income (ttm)	-193.51M
Shares Out	159.02M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,589,232
Open	6.57
Previous Close	6.41
Day's Range	6.21 - 7.20
52-Week Range	4.06 - 11.78
Beta	1.49
Analysts	Strong Buy
Price Target	16.22 (+128.13%)
Earnings Date	May 6, 2025

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 274
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL
• Website: https://www.ocutx.com

Financial Performance

In 2024, Ocular Therapeutix's revenue was $63.72 million, an increase of 9.03% compared to the previous year's $58.44 million. Losses were -$193.51 million, 139.7% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price forecast is $16.22, which is an increase of 128.13% from the latest price.

Price Target

$16.22

(128.13% upside)

Analyst Consensus: Strong Buy